

Ulrike Haug

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3298794/publications.pdf>

Version: 2024-02-01

96
papers

4,711
citations

117571

34
h-index

98753

67
g-index

110
all docs

110
docs citations

110
times ranked

5924
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery – an analysis of German claims data. <i>BMC Cancer</i> , 2022, 22, 130.	1.1	1
2	How often are antidepressants prescribed off-label among older adults in Germany? A claims data analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1778-1789.	1.1	4
3	German Pharmacoepidemiological Research Database (GePaRD). <i>Springer Series on Epidemiology and Public Health</i> , 2021, , 119-124.	0.5	12
4	Prescribing of menopausal hormone therapy in Germany: Current status and changes between 2004 and 2016. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 462-471.	0.9	5
5	Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries. <i>Frontiers in Oncology</i> , 2021, 11, 630456.	1.3	7
6	Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. <i>Cancer Epidemiology</i> , 2021, 71, 101812.	0.8	3
7	Potential of German claims data to characterize utilization of new cancer drugs: the example of crizotinib. <i>Future Oncology</i> , 2021, 17, 2305-2313.	1.1	1
8	Characterization of pregnancies exposed to St. John's wort and their outcomes: A claims data analysis. <i>Reproductive Toxicology</i> , 2021, 102, 90-97.	1.3	2
9	Avoiding Time-Related Biases: A Feasibility Study on Antidiabetic Drugs and Pancreatic Cancer Applying the Parametric g-Formula to a Large German Healthcare Database. <i>Clinical Epidemiology</i> , 2021, Volume 13, 1027-1038.	1.5	3
10	Follow-up of 3 Million Persons Undergoing Colonoscopy in Germany: Utilization of Repeat Colonoscopies and Polypectomies Within 10 Years. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00279.	1.3	8
11	Associations between comorbidities and advanced stage diagnosis of lung, breast, colorectal, and prostate cancer: A systematic review and meta-analysis. <i>Cancer Epidemiology</i> , 2021, 75, 102054.	0.8	14
12	Characterization of pregnancies among women with epilepsy using valproate before or during pregnancy - A longitudinal claims data analysis. <i>Epilepsy Research</i> , 2021, 179, 106838.	0.8	0
13	Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis. <i>Journal of Internal Medicine</i> , 2020, 287, 171-179.	2.7	10
14	Linkage of Routine Data to Other Data Sources in Germany: A Practical Example Illustrating Challenges and Solutions. <i>Gesundheitswesen</i> , 2020, 82, S117-S121.	0.8	5
15	Promises and Potential Pitfalls of Shared Decision Making in Cancer Screening. <i>Gastroenterology</i> , 2020, 158, 802-805.	0.6	1
16	Estimating the Beginning of Pregnancy in German Claims Data: Development of an Algorithm With a Focus on the Expected Delivery Date. <i>Frontiers in Public Health</i> , 2020, 8, 350.	1.3	10
17	Different Risk Profiles of European Patients Using Direct Oral Anticoagulants or Vitamin K Antagonists: a Rapid Review. <i>Current Epidemiology Reports</i> , 2020, 7, 290-299.	1.1	1
18	<p><p>Individual Antidepressants and the Risk of Fractures in Older Adults: A New User Active Comparator Study</p></p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 667-678.	1.5	5

#	ARTICLE	IF	CITATIONS
19	The cumulative false-positive rate in colorectal cancer screening: a Markov analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 575-580.	0.8	3
20	Screening des kolorektalen Karzinoms. <i>Springer Reference Medizin</i> , 2020, , 1-4.	0.0	0
21	Incidence of advanced colorectal cancer in Germany: comparing claims data and cancer registry data. <i>BMC Medical Research Methodology</i> , 2019, 19, 142.	1.4	14
22	Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. <i>BMJ: British Medical Journal</i> , 2019, 367, l5383.	2.4	79
23	<p>Antidepressants and the risk of traumatic brain injury in the elderly: differences between individual agents</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 185-196.	1.5	5
24	Individual mortality information in the German Pharmacoepidemiological Research Database (GePaRD): a validation study using a record linkage with a large cancer registry. <i>BMJ Open</i> , 2019, 9, e028223.	0.8	15
25	Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 39-45.	0.7	7
26	Implementation of an algorithm for the identification of breast cancer deaths in German health insurance claims data: a validation study based on a record linkage with administrative mortality data. <i>BMJ Open</i> , 2019, 9, e026834.	0.8	10
27	Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes. <i>International Journal of Colorectal Disease</i> , 2019, 34, 269-276.	1.0	25
28	First-degree relatives of cancer patients: a target group for primary prevention? A cross-sectional study. <i>British Journal of Cancer</i> , 2018, 118, 1255-1261.	2.9	13
29	Utilization of colonoscopy and colonoscopic findings among individuals aged 40â€“54 years with a positive family history of colorectal cancer: a cross-sectional study in general practice. <i>European Journal of Cancer Prevention</i> , 2018, 27, 539-545.	0.6	2
30	Invitation to Screening Colonoscopy in the Population at Familial Risk for Colorectal Cancer. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 715-722.	0.6	10
31	Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1005-1010.	0.9	21
32	World Endoscopy Organization Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer. <i>Gastroenterology</i> , 2018, 155, 909-925.e3.	0.6	221
33	A cohort study of mammography screening finds that comorbidity measures are insufficient for controlling selection bias. <i>Journal of Clinical Epidemiology</i> , 2018, 104, 1-7.	2.4	4
34	Flexible sigmoidoscopy screening for colorectal cancer. <i>BMJ: British Medical Journal</i> , 2017, 356, j75.	2.4	2
35	Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?. <i>Gut</i> , 2017, 66, 1262-1267.	6.1	18
36	Arzneimittel in der Schwangerschaft â€“ Potenzial von SekundÃrdaten. <i>Public Health Forum</i> , 2017, 25, 221-223.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Strategies for prevention of gastrointestinal cancers in developing countries: a systematic review. <i>Journal of Global Health</i> , 2017, 7, 020405.	1.2	11
38	Recommendations for a stepwise comparative approach to the evaluation of new screening tests for colorectal cancer. <i>Cancer</i> , 2016, 122, 826-839.	2.0	24
39	Validity of self-reported family history of cancer: A systematic literature review on selected cancers. <i>International Journal of Cancer</i> , 2016, 139, 1449-1460.	2.3	43
40	Development of new non-invasive tests for colorectal cancer screening: The relevance of information on adenoma detection. <i>International Journal of Cancer</i> , 2015, 136, 2864-2874.	2.3	17
41	Association between socioeconomic and demographic characteristics and utilization of colonoscopy in the EPIC-Heidelberg cohort. <i>European Journal of Cancer Prevention</i> , 2015, 24, 81-88.	0.6	8
42	Estimating Colorectal Cancer Treatment Costs: A Pragmatic Approach Exemplified by Health Insurance Data from Germany. <i>PLoS ONE</i> , 2014, 9, e88407.	1.1	36
43	Interval cancer: nightmare of colonoscopists: Table 1. <i>Gut</i> , 2014, 63, 865-866.	6.1	7
44	Consideration of family history of cancer in medical routine. <i>European Journal of Cancer Prevention</i> , 2014, 23, 199-205.	0.6	6
45	Vitamin D receptor polymorphism and colorectal cancer-specific and all-cause mortality. <i>Cancer Epidemiology</i> , 2013, 37, 905-907.	0.8	21
46	Genetic Variations in the Vitamin D Binding Protein and Season-Specific Levels of Vitamin D Among Older Adults. <i>Epidemiology</i> , 2013, 24, 104-109.	1.2	25
47	Vitamin D Receptor Genotype rs731236 (Taq1) and Breast Cancer Prognosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 437-442.	1.1	22
48	Serum 25-Hydroxyvitamin D and Cancer Risk in Older Adults: Results from a Large German Prospective Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 905-916.	1.1	61
49	Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. <i>American Journal of Clinical Nutrition</i> , 2013, 97, 782-793.	2.2	238
50	Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. <i>British Journal of Cancer</i> , 2012, 106, 1424-1430.	2.9	47
51	Public health implications of standardized 25-hydroxyvitamin D levels: A decrease in the prevalence of vitamin D deficiency among older women in Germany. <i>Preventive Medicine</i> , 2012, 55, 228-232.	1.6	27
52	A novel multiplex-protein array for serum diagnostics of colon cancer: a case-control study. <i>BMC Cancer</i> , 2012, 12, 393.	1.1	34
53	Subsite-specific colorectal cancer risk in the colorectal endoscopy era. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 621-630.e1.	0.5	39
54	786 Effectiveness and Cost-Effectiveness of Once-Only Screening for Colorectal Cancer With Colonoscopy or Computed Tomographic Colonography. <i>Gastroenterology</i> , 2012, 142, S-141-S-142.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Standardization of Misleading Immunoassay Based 25-Hydroxyvitamin D Levels with Liquid Chromatography Tandem-Mass Spectrometry in a Large Cohort Study. PLoS ONE, 2012, 7, e48774.	1.1	46
56	How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysis. International Journal of Cancer, 2012, 131, 2094-2102.	2.3	7
57	Glutathione peroxidase tagSNPs: Associations with rectal cancer but not with colon cancer. Genes Chromosomes and Cancer, 2012, 51, 598-605.	1.5	19
58	Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy. Gastrointestinal Endoscopy, 2011, 73, 435-443.e5.	0.5	38
59	Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. British Journal of Cancer, 2011, 104, 1779-1785.	2.9	108
60	Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecologic Oncology, 2011, 121, 369-375.	0.6	78
61	Meta-analysis: Serum vitamin D and colorectal adenoma risk. Preventive Medicine, 2011, 53, 10-16.	1.6	55
62	Authors' reply to: Acceptance quality checks for qualitative fecal immunochemical tests ensure screening program consistency. International Journal of Cancer, 2011, 128, 248-249.	2.3	0
63	Toward Standardized High-Throughput Serum Diagnostics: Multiplex Protein Array Identifies IL-8 and VEGF as Serum Markers for Colon Cancer. Journal of Biomolecular Screening, 2011, 16, 1018-1026.	2.6	44
64	Performance of Immunochemical Fecal Occult Blood Tests Among Users of Low-Dose Aspirin Reply. JAMA - Journal of the American Medical Association, 2011, 305, 1093.	3.8	0
65	Sensitivity Estimates of Blood-Based Tests for Colorectal Cancer Detection: Impact of Overrepresentation of Advanced Stage Disease. American Journal of Gastroenterology, 2011, 106, 242-253.	0.2	28
66	Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Review of Molecular Diagnostics, 2011, 11, 605-616.	1.5	37
67	Low-Dose Aspirin Use and Performance of Immunochemical Fecal Occult Blood Tests. JAMA - Journal of the American Medical Association, 2010, 304, 2513.	3.8	119
68	Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. International Journal of Cancer, 2010, 127, 1643-1649.	2.3	38
69	Response: Re: Protection From Right- and Left-Sided Colorectal Neoplasms After Colonoscopy: Population-Based Study. Journal of the National Cancer Institute, 2010, 102, 990-991.	3.0	1
70	Sex Differences in Performance of Fecal Occult Blood Testing. American Journal of Gastroenterology, 2010, 105, 2457-2464.	0.2	115
71	Protection From Right- and Left-Sided Colorectal Neoplasms After Colonoscopy: Population-Based Study. Journal of the National Cancer Institute, 2010, 102, 89-95.	3.0	546
72	Colonoscopy Use in a Country with a Long-Standing Colorectal Cancer Screening Programme: Evidence from a Large German Survey. Zeitschrift Fur Gastroenterologie, 2010, 48, 1351-1357.	0.2	10

#	ARTICLE	IF	CITATIONS
73	Male Sex and Smoking Have a Larger Impact on the Prevalence of Colorectal Neoplasia Than Family History of Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 870-876.	2.4	79
74	Population-based prevalence estimates of history of colonoscopy or sigmoidoscopy: review and analysis of recent trends. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 366-381.e2.	0.5	53
75	Low Risk of Colorectal Cancer and Advanced Adenomas More Than 10 Years After Negative Colonoscopy. <i>Gastroenterology</i> , 2010, 138, 870-876.	0.6	132
76	Quantitative Immunochemical Fecal Occult Blood Testing for Colorectal Adenoma Detection: Evaluation in the Target Population of Screening and Comparison With Qualitative Tests. <i>American Journal of Gastroenterology</i> , 2010, 105, 682-690.	0.2	83
77	Meta-analysis: Serum vitamin D and breast cancer risk. <i>European Journal of Cancer</i> , 2010, 46, 2196-2205.	1.3	182
78	Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 113-125.	1.9	179
79	Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. <i>Cancer Epidemiology</i> , 2009, 33, 435-445.	0.8	87
80	Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: Estimates based on 1,875,708 screening colonoscopies. <i>European Journal of Cancer</i> , 2009, 45, 2027-2033.	1.3	60
81	Comparative Evaluation of Immunochemical Fecal Occult Blood Tests for Colorectal Adenoma Detection. <i>Annals of Internal Medicine</i> , 2009, 150, 162.	2.0	295
82	Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. <i>British Journal of Cancer</i> , 2008, 99, 133-135.	2.9	54
83	Should colorectal cancer screening start at the same age in European countries? Contributions from descriptive epidemiology. <i>British Journal of Cancer</i> , 2008, 99, 532-535.	2.9	21
84	Reply: Faecal tumour pyruvate kinase M2: not a good marker for detection of colorectal adenomas. <i>British Journal of Cancer</i> , 2008, 99, 1367-1367.	2.9	2
85	Evaluation of Serum and Urinary Myeloid Related Protein-14 as a Marker for Early Detection of Prostate Cancer. <i>Journal of Urology</i> , 2008, 180, 1309-1313.	0.2	24
86	Family History and Age at Initiation of Colorectal Cancer Screening. <i>American Journal of Gastroenterology</i> , 2008, 103, 2326-2331.	0.2	35
87	Stool testing for the early detection of pancreatic cancer: rationale and current evidence. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 753-759.	1.5	32
88	Gender differences in colorectal cancer: implications for age at initiation of screening. <i>British Journal of Cancer</i> , 2007, 96, 828-831.	2.9	195
89	Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. <i>British Journal of Cancer</i> , 2007, 96, 1329-1334.	2.9	49
90	Mutant-Enriched PCR and Allele-Specific Hybridization Reaction to Detect K-ras Mutations in Stool DNA: High Prevalence in a Large Sample of Older Adults. <i>Clinical Chemistry</i> , 2007, 53, 787-790.	1.5	29

#	ARTICLE	IF	CITATIONS
91	Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840 149 screening colonoscopies. <i>Gut</i> , 2007, 56, 1585-1589.	6.1	338
92	Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1935-1953.	1.1	189
93	Reply: New faecal tests for colorectal cancer screening: is tumour pyruvate kinase M2 one of the options?. <i>British Journal of Cancer</i> , 2007, 97, 1597-1597.	2.9	1
94	Tumor M2 Pyruvate Kinase as a Stool Marker for Colorectal Cancer: Stability at Room Temperature and Implications for Application in the Screening Setting. <i>Clinical Chemistry</i> , 2006, 52, 782-784.	1.5	13
95	New stool tests for colorectal cancer screening: A systematic review focusing on performance characteristics and practicalness. <i>International Journal of Cancer</i> , 2005, 117, 169-176.	2.3	33
96	A Simulation Model for Colorectal Cancer Screening: Potential of Stool Tests with Various Performance Characteristics Compared with Screening Colonoscopy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 422-428.	1.1	21